TARRYTOWN, N.Y., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive three-year (156-week) data for EYLEA HD ® (aflibercept) Injection 8 mg from ...
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) reported results from phase 2 proof-of-concept trial evaluating an investigational 8 mg high dose of aflibercept compared to the currently-approved 2 ...
Patients with prior treatment for diabetic macular edema (DME) may require more frequent dosing of aflibercept (Eylea), according to a subgroup analysis of the PHOTON trial presented at the recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback